Synspira raises $8m for inhaled pulmonary therapies

Privately-held Synspira said today that raised $8 million from an unnamed private investor to bring its inhaled cystic fibrosis therapy into a Phase I safety study.

The Boston-based company was founded earlier this year and is focused on developing inhaled therapies for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disease and pneumonia. Synspira holds an exclusive field license to Synedgen’s Glycomics Technology platform and its pulmonary delivery assets.

Get the full story at our sister site, Drug Delivery Business News.

The post Synspira raises $8m for inhaled pulmonary therapies appeared first on MassDevice.

from MassDevice http://ift.tt/2sl6MHF

Bonesupport closes $57m IPO

BoneSupport said last week it closed its initial public offering, raising a total of approximately $57.1 million (SEK 500 million), not including an over-allotment option.

The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it floated approximately 17.2 million new shares at $3.40 per share (SEK 29) in the round, raising approximately $57.1 million before issue costs and $54 million (SEK 461 million) after issue costs.

Read the whole story at our sister site, Drug Delivery Business

The post Bonesupport closes $57m IPO appeared first on MassDevice.

from MassDevice http://ift.tt/2t4z4Dj

MetaStat lands $7m for personalized cancer diagnostic, therapy tech

MetaStat (OTC:MTST) said this week that it closed the 1st tranche of a $7 million private placement.

The round, which was led by Perceptive Advisors, is slated to bring in approximately $2.1 million, according to the Boston-based company.

Get the full story at our sister site, Drug Delivery Business News.

The post MetaStat lands $7m for personalized cancer diagnostic, therapy tech appeared first on MassDevice.

from MassDevice http://ift.tt/2tocUib

Topical post-herpetic neuralgia treatment fails to meet primary endpoint in Phase II

Teva Pharmaceuticals (NYSE:TEVA) and Xenon Pharmaceuticals (NSDQ:XENE) said this week that the Phase II study of a topical post-herpetic neuralgia treatment did not meet its primary or secondary endpoints.

The small-molecule inhibitor, TV-45070, was licensed by Xenon to Teva in December 2012.

Get the full story at our sister site, Drug Delivery Business News.

The post Topical post-herpetic neuralgia treatment fails to meet primary endpoint in Phase II appeared first on MassDevice.

from MassDevice http://ift.tt/2tZRmWB

K2M wins FDA nod for Capri 3D-printed corpectomy cage

K2M (NSDQ:KTWO) said today it won FDA 510(k) clearance for its Capri small 3D static corpectomy cage system, touing it as the 1st-to-market 3D-printed, FDA-cleared device of its kind.

The newly cleared device is designed for stabilizing the thoracolumbar spine during vertebral body resections as a result of trauma or tumors, the Leesburg, Va.-based company said. The device has a porous structure and rough surface architecture to allow for bony integration through it, and features lordotic options to help support the anterior spinal column to help achieve sagittal balance.

Read the whole story on our sister site, Medical Design & Outsourcing

The post K2M wins FDA nod for Capri 3D-printed corpectomy cage appeared first on MassDevice.

from MassDevice http://ift.tt/2s3df61

NY Rep. Collins loses millions on Innate flop

Earlier this year, Rep. Chris Collins’ (R-NY) 16.8% stake in Innate Immunotherapeutics (ASX:IIL) was worth $45.5 million. But since the Australian biotech’s lead drug failed in a 93-patient trial this week, shares in the company dropped to 4¢ apiece and Collins’ holdings are now valued at just $1.5 million.

As the company’s largest investor and a board member, Collins has previously encouraged his congressional colleagues to back the company. Elected officials who have purchased stock based on Collins’ recommendation includes now Health and Human Services Secretary Tom Price, who bought Innate shares in 2015 and 2016 while he was a member of the House

Get the full story at our sister site, Drug Delivery Business News.

The post NY Rep. Collins loses millions on Innate flop appeared first on MassDevice.

from MassDevice http://ift.tt/2t21Rsh

6 surgical robots that will surprise you

[Image from unsplash.com]

Researchers around the globe have created surgical robots for solutions to procedures that are generally invasive and time-consuming. Whether its eye surgery or even finding a vein to draw blood, healthcare practitioners face daunting tasks, but robots have made these procedures easier (as easy as the DaVinci makes it look when peeling a grape and stitching it back together).

From robots that locate veins and draw blood to a robotic drill that drills into the skin 50 times faster than standard procedures, here are 6 surgical robots that are innovating surgery and healthcare.

Next >>

The post 6 surgical robots that will surprise you appeared first on MassDevice.

from MassDevice http://ift.tt/2tma38W